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Abstract—Programmed cell death 5 (PDCD5) was first identified as a gene upregulated in cells
undergoing apoptosis. We recently demonstrated the inhibitory effect of PDCD5 on experimentally
induced autoimmune encephalomyelitis. In this study, we investigated the anti-inflammatory effects of
recombinant human PDCD5 (rhPDCD5) in a rat collagen-induced arthritis (CIA) model. We find that
vaccination of collagen II (CII) induced CIA rats with rhPDCD5 significantly delayed the occurrence
and reduced the severity of CIA rats. rhPDCD5 also restored the loss of Foxp3+ regulatory T (Treg) cells
and decreased the population of Th1 and Th17 in CIA rats. Simultaneously, rhPDCD5 treatment
suppressed the production of pro-inflammatory cytokines (interleukin (IL)-6, IL-17A, tumor necrosis
factor-α (TNF-α), and interferon gamma (IFN-γ)) and increased the secretion of anti-inflammatory
cytokines (transforming growth factor beta 1 (TGF-β1) and IL-10) in CIA rats. In addition, rhPDCD5
inhibited the ability of CII to induce proliferation of splenocytes and lymph node cells (LNCs) and
promoted the CII-activated CD4+ cell apoptosis. These results of rhPDCD5-treated CIA rats were
similar with those of recombinant human TNF-α receptor IgG Fc (rhTNFR:Fc). Thus, to our knowledge,
we provide the first evidence that rhPDCD5 may be an efficient approach to diminishing exacerbated
immune responses in CIA, indicating its therapeutic potential in the treatment of rheumatoid arthritis and
other autoimmune diseases.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic,
inflammatory disease, characterized by inflammatory cell
infiltration in the synovial tissue, synovial pannus forma-
tion, and it results in subsequent bone erosions, leading to
joint destruction and progressive disability. Although the
etiology and pathogenesis of RA remain unknown, many
studies suggest that pathogenic T cells, such as Th1 and
Th17 cells, are activated during the disease process and
accumulated in the inflamed synovium, leading to perpet-
uation of inflammation with massive tissue destruction [1].
On the other hand, there is ample evidence that
CD4+CD25+Foxp3+ regulatory T (Treg) cells also play a
critical role in autoimmune diseases, including RA [2].
Their numbers and activation status are associated with
RA activity in general. Thus, therapeutic strategies
targeting RA should consider the upregulation of Treg cell
differentiation, as well as the inhibition of pro-
inflammatory cells and pro-inflammatory cytokines.
Programmed cell death 5 (PDCD5) was first identi-
fied as an apoptosis-promoting protein [3]. The decreased
expression of PDCD5 has been detected in many human
tumors, and restoration of PDCD5 with recombinant pro-
tein can significantly sensitize different cancer cells to
chemotherapies [4–7]. Recombinant human PDCD5
(rhPDCD5) has been shown to enter a variety of cells by
clathrin-independent endocytosis and exert biological ac-
tivities [7]. Studies on molecular mechanism of PDCD5
have been proposed that PDCD5 interacts with the histone
acetyltransferase Tip60 and the transcription factor p53 to
promote apoptosis [8–10]. PDCD5 can also interact with
other molecules such as NF-κB p65 [11] and CCT [12], in
which participate in the regulation of cell apoptosis.
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Clinical literature suggests that PDCD5 is involved in
some autoimmune diseases and inflammatory processes
[13–19]. In patients with RA, the levels of PDCD5 protein
are inversely associated with the levels of pro-
inflammatory cytokines interleukin (IL)-17 and tumor ne-
crosis factor-α (TNF-α) [17, 18]. In patients with psoriasis,
the downregulated level of PDCD5 mRNA is closely
linked with its DNA methylation [19]. Recently, we have
shown that PDCD5 interacts with Foxp3, increases acety-
lation of Foxp3 in synergy with Tip60 and enhances the
repressive function of Foxp3 [20]. In PDCD5 transgenic
mice, overexpression of PDCD5 increased the level of
Foxp3 protein and percentage of CD4+CD25+Foxp3+
cells, alleviating the severity of experimentally induced
autoimmune encephalomyelitis (EAE) in PDCD5tg mice.
The beneficial effect of PDCD5 resulted from increases of
Treg cell frequency, reducing the predominant pathogenic
Th17/Th1 response. This is the first report revealing that
PDCD5 activity in T cells suppresses autoimmunity by
modulating Foxp3-Tregs axis [20].
In view of the fact that rhPDCD5 can enter cells and
exert biological activities [21], the present study was de-
signed to assess the efficacy of rhPDCD5 in collagen-
induced arthritis (CIA) rats. Data obtained from experi-
ments indicate that rhPDCD5 has an anti-inflammatory
effect in CIA rats.
MATERIALS AND METHODS
Reagents and Antibodies
Bovine type II collagen (CII) and complete Freund’s
adjuvant (CFA) were purchased from Chondrex (Red-
mond, WA, USA). Anti-interferon gamma (IFN-γ) and
anti-IL-17A antibodies were purchased from BD (San
Diego, CA, USA). Foxp3 intracellular staining kit and
cytokine detecting enzyme-linked immunosorbent assay
(ELISA) kits were purchased from eBioscience (San
Diego, CA, USA). Recombinant human tumor necrosis
factor-α receptor IgG Fc fusion protein (rhTNFR:Fc) was
obtained from Shanghai CP Guojian Pharmaceutical Co.,
Ltd (Shanghai, China). Phorbol 12-myristate13-acetate
(PMA) and ionomycin were purchased from Sigma-
Aldrich (St Louis, MO, USA) Recombinant human
PDCD5 protein was supplied by Beijing Biosea Biotech-
nology Co., Ltd (Beijing, China). The endotoxin activity of
the PDCD5 protein received was <10 EU/mg as detected
using the limulus amebocyte lysate assay, and the purity of
the rhPDCD5 protein was >95 %.
Induction, Treatment, and Measurement of CIA
in Rats
Female Wistar rats (150 to 200 g) were obtained from
the Deparment of Laboratory Animal Science (Peking
University Health Science Center, Beijing, China). They
were kept under pathogen-free conditions and had free
access to food and water during the experimental period.
The experiments were conducted in a facility accredited by
the Association for Assessment and Accreditation of Lab-
oratory Animal Care (AAALAC) and conducted under
Institutional Animal Care and Use Committee guidelines.
Experimental rats were randomly divided into four
groups, including normal group, CIA + ovalbumin (OVA)
group, CIA + rhTNFR:Fc group, and CIA + rhPDCD5
group. On day 0, all arthritic rats were intradermally
injected with 0.5-mL CFA emulsion containing 200 μg
CII at the back and base of the tail, followed by a booster
injection 7 days later using the same method. The normal
rats were injected with 0.5-mL sterilized physiological
saline only. During the experiment, an optimal dose of
rhPDCD5 (14 mg/kg) was injected intraperitoneally on
alternate days from day 2 to day 26. As control, OVA
(14 mg/kg) was injected in the same manner. RhTNFR:Fc
(3.5 mg/kg, positive control) was injected every 3 days
from day 2 to day 26. The CIA clinical score for each
carpal tarsal joint of the rats was evaluated as follows: 0=
normal, 1=slight swelling and erythema, 2=pronounced
edema, and 3=joint rigidity. Scores for the four carpal
tarsal joints measured each week were combined to give
a global clinical score of a maximum of 12 for each rat.
Tissue Preparation and Histomorphological
Evaluation
For histological morphology analysis, rats were killed
on day 28 after the first immunization and carpal tarsal
joints of rats in each group were removed and fixed in 4 %
paraformaldehyde (pH 7.4) for 25 h. Decalcification was
completed in 10 % EDTA solution, and then the samples
were embedded in paraffin. Thereafter, they were cut into
5-μm sagittal sections and stained with hematoxylin and
eosin (H&E) and safranin O dye. Histopathological images
of carpal tarsal joints were taken by light microscope.
Histopathological assessments were coded for blind obser-
vation, and carpal tarsal joints were scored histopatholog-
ically using a qualitative scale from 0 to 4 based on the
degree of inflammation, pannus formation, cartilage de-
struction, and bone erosion associated with arthritis. The
scoring scale was defined as follows: 0, no lesion; 1,
minimal inflammatory infiltration; 2, mild inflammatory
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infiltration and synovial hyperplasia; 3, pannus formation
with cartilage degeneration; and 4, heavy inflammatory
infiltration and debris in the joint, severe chondrocytes,
and cartilage matrix loss with new bone tissue substitution,
bone destruction.
Flow Cytometry Analysis
The spleen and draining lymph nodes (LNs) from the
different groups were harvested at 28 days after the first
immunization to prepare single-cell suspensions. Peripher-
al blood mononuclear cells (PBMCs) were prepared using
Ficoll-Paque separation media (Dakewei, Shenzhen, Chi-
na). To quantify the number of Tregs, splenocytes, lymph
node cells (LNCs), and PBMCs were surface-stained with
anti-rat CD4-FITC/CD25-APC. After fixation at 4 °C for
30 min, cells were permeabilized and stained with anti-rat
Foxp3-PE antibody. The stained cells were detected using
the FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA, USA).
To quantify IFN-γ and IL-17 expressions in CD4+ T
cell, cells were stimulated with PMA plus ionomycin in the
presence of brefeldin A for 5 h, followed by surface
staining with anti-rat CD4-FITC and permeabilization for
staining with anti-rat IFN-γ-PE and IL-17-PE. The stained
cells were detected by the FACSCalibur flow cytometer as
previously described [20].
Apoptosis Assay
The Annexin V-FITC Apoptosis Detection Kit (Bei-
jing Biosea Biotechnology Co., Ltd., Beijing, China) was
used according to the manufacturer’s instructions. Briefly,
LNCs from different rats were harvested and stimulated
with 20 μg/ml of CII. After 48 h, cells were collected and
stained with anti-rat CD4-PE and AnnexinV-FITC, and
percentages of CD4+Annexin V+ double positive cells
were analyzed by the FACSCalibur flow cytometer.
Detection of Cytokines
Serum and knee joint synovial fluids from different
group were collected at 28 days after the first immuniza-
tion, and concentrations of cytokines were measured using
ELISA kits according to the manufacturer’s instructions.
The withdrawal of synovial fluid was performed as fol-
lows: joint cavity was opened; the patellar ligament was
carefully removed; and then 200 μl of 0.9 % NaCl was
injected intraarticularly into each knee. Subsequently, the
synovial fluid was aspirated with the same syringe.
For detecting cytokines in culture supernatants,
splenocytes and LNCs collected from each group were
plated (5×105 cells/well) in 96-well plates and stimulated
in triplicate wells with 20 μg/ml of CII. After 48 h, cyto-
kine levels in the supernatants were detected by ELISA
kits.
Lymphocyte Proliferation Assay
Splenocytes and LNCs from different rats were seed-
ed at 5×105 cells/well in 96-well plates and stimulated with
20 μg/ml of CII for 48 h. Then, cells were pulsed with
1 μCi/well [3H] thymidine (MP Biomedicals, USA) and
incubated for additional 8 h. The results were expressed as
mean [3H] thymidine incorporation (cpm) ± standard de-
viation (SD).
Statistical Analysis
The results were evaluated using ANOVA with sub-
sequent comparisons by Student t test for paired or
nonpaired data, as appropriate. Statistical significance
was defined as p<0.05.
RESULTS
rhPDCD5 Suppresses CIA Development and Protects
Against Joint Destruction
To investigate the in vivo role of rhPDCD5 in the
regulation of autoimmune diseases, we used a well-
established CIA rat model which displayed many of the
pathological features of human RA [22]. This arthritic rat
model has been used extensively to analyze the anti-
inflammatory effects of newly developed drugs on chronic
arthritis.
Arthritic rats were seen on day 11∼12 in OVA + CIA
rats and reached a peak on day 20 after the induction of
CIA (Fig. 1a, b and c). In contrast, CIA rats treated with
either rhPDCD5 or rhTNFR:Fc showed a delayed onset of
disease, as well as significant reductions in mean clinical
score and paw swelling. Rats treated with either rhPDCD5
or rhTNFR:Fc showed less tumid of paws than the control
group (Fig. 1d). OVA + CIA rats had markedly enlarged
inguinal LN, which were much larger than either
rhPDCD5- or rhTNFR:Fc-treated CIA rats (Fig. 1e). Total
lymphocytes of inguinal LN were also counted, and
rhPDCD5 + CIA rats had significantly fewer lymphocytes
compared to OVA + CIA rats. Similar trend was observed
in rhTNFR:Fc + CIA rats (Fig. 1f).
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The benefit of rhPDCD5 on CIA rats was fur-
ther verified by histological examination. At day 28
after immunization, carpal tarsal joints of CIA rats
were examined after H&E and safranin O staining.
We observed that OVA + CIA rats developed inflam-
matory cell infiltration, pannus formation, cartilage
destruction, and bone erosion with pannus replacing
the articular cartilage overlying the bone. In contrast,
the histological appearance of the carpal tarsal joints
in rhPDCD5 + CIA rats demonstrated well-preserved
joint space with minimal inflammatory exudates, nor-
mal structure of knee cartilage, and subchondral bone
(Fig. 2a). Consistent with observations, the average
histological score was markedly lower in rhPDCD5 +
CIA rats compared with the OVA + CIA group, and
similar trend was observed in rhTNFR:Fc + CIA rats
(Fig. 2a, b).
rhPDCD5 Increases Treg Frequency but Reduces Th1
and Th17 Response in CIA Rats
Previous studies demonstrated that the percentages of
Tregs are increased, and Th17/Th1 effectors are decreased
in PDCD5tg mice with EAE [19]. We want to know
whether rhPDCD5-treated CIA rats can also exhibit similar
results. Therefore, we assessed the profiles of CD4+ T cell
Fig. 1. rhPDCD5 induces protective effects against CIA. a Incidence of CIA, defined as a total arthritis score ≥2 in each rat (n=6). b Severity of arthritis
during the course of CIA, as evaluated by the arthritis score (*P<0.05 vs. CIA + OVA, n=6). c Paw swelling was individually evaluated by the volumetric
method described in the “MATERIALS ANDMETHODS” section (*P<0.05 vs. CIA + OVA, n=6). d Photographs of the hind paws and fore paws on day
28 after the first CII immunization. eRepresentative of inguinal LN from different groups. f Total counts of lymphocytes in inguinal LN from different groups
(n=6).
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subsets in splenocytes, LNCs, and PBMCs from different
CIA rats. As shown in Fig. 3a, b and c, the percentage of
CD4+CD25+Foxp3+ Tregs was significantly increased in
rhPDCD5 + CIA rats, compared with the OVA + CIA rats.
Similar results were observed in the rhTNFR:Fc + CIA
group. Interestingly, rhPDCD5 + CIA rats showed a higher
population of Tregs in LN, compared with rhTNFR:Fc +
CIA group (Fig. 3d). Simultaneously, the frequency of
CD4+IFN-γ+ Th1 and CD4+IL-17A+ Th17 cells in
rhPDCD5 + CIA and rhTNF:Fc + CIA rats was
significantly decreased compared with OVA + CIA rats
(Fig. 3e).
rhPDCD5Decreases the Production of Pro-Inflammatory
Cytokines and Increases Anti-Inflammatory Cytokines
in CIA Rats
Treg cells suppress immune response through numer-
ous mechanisms, including the production of anti-
inflammatory cytokines and direct cell to cell contact.
Therefore, we further examined the effect of rhPDCD5
on the levels of various pro-inflammatory and anti-
inflammatory cytokines in CIA rats. As shown in Fig. 4a,
b, rhPDCD5 significantly decreases the levels of IL-6, IL-
17A, TNF-α, and IFN-γ, while increases the levels of
TGF-β1 and IL-10 both in serum and synovial, compared
with OVA + CIA rats. RhTNFR:Fc + CIA group showed
similar effects to rhPDCD5. Moreover, rhPDCD5 + CIA
rats showed higher levels of TGF-β1 both in serum and
synovial than rhTNFR:Fc + CIA rats (Fig. 4a, b).
Further, we examined the cytokine production by
draining LNCs and splenocytes ex vivo. Single-cell sus-
pensions were cultured in the presence of bovine CII
(20 μg/ml) for 48 h, and supernatants were analyzed by
ELISA. It was clear that the production of IFN-γ and IL-
17A were decreased in cultured LNCs and splenocytes
from either rhTNFR:Fc- or rhPDCD5-treated CIA rats,
compared to those OVA-treated group (Fig. 4c, d), whereas
the levels of IL-10 were increased.
rhPDCD5 Suppresses CII-Induced Cell Proliferation
and Promotes Cell Apoptosis
To further determine whether rhPDCD5 could
inhibit CII-specific lymphocyte responses, LNCs and
splenocytes isolated from the different groups were
stimulated in vitro with CII. Compared to the cells
isolated from the control group, CII obviously stim-
ulated the proliferation of both LNCs and splenocytes
obtained from OVA + CIA rats. On the contrary, CII
was less potent in stimulating the proliferation of
LNCs and splenocytes isola ted from ei ther
rhTNFR:Fc- or rhPDCD5-treated CIA rats (Fig. 5a).
There was no significant difference between
rhTNFR:FC and rhPDCD5 in terms of CII-specific
lymphocyte responses.
Previous studies indicated that rhPDCD5 could pro-
mote cell apoptosis in variety of tumor cell [4–7]. We next
investigated the effect of rhPDCD5 on activation-induced
cell apoptosis in CII-stimulated CD4+ T cells. The
treatment of LNCs was as same as cell proliferation
assay. Treated LNCs were stained with anti-CD4-PE and
FITC-Annexin V (AV) and analyzed by flow cytometry.
We found that the percentage of CD4+AV+ cells were
increased in either rhPDCD5- or rhTNFR:Fc-treated rats
compared to that OVA + CIA rats (Fig. 5b). Importantly,
the percentage of apoptosis from rhPDCD5 + CIA rats was
larger than that of rhTNFR:Fc + CIA group.
Fig. 2. rhPDCD5 alleviates inflammatory histopathology of CIA. Histological examination of ankle joints. a Histology samples of carpal tarsal joints from
four groups were stained with H&E and safranin O dye and observed with light microscope (original magnification ×100). Images are representative of n=6
rats per group. b Histological scores of the four individual carpal tarsal joints were averaged for each rat, and mean scores for six rats selected per group are
shown (***P<0.0005).
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DISCUSSION
CIAmodel is commonly used to study human RA for
its pathological, immunological, and clinical similarities.
The fact that the inflammatory process in RA is chronic
suggests that immune regulation in RA is disturbed. This
disturbance is likely caused by an excessive inflammatory
response together with a deficiency in the mechanisms that
control the immune response.
We previous reported that PDCD5tgmice exhibited a
systemic anti-inflammatory condition in EAEmice [20]. In
the present study, we showed that rhPDCD5 possessed a
similarly anti-inflammatory effect compared with
rhTNFR:Fc, by diminishing the severity of arthritis and
inhibiting the progression of CIA in rats. This strong
efficacy may be associated with the increase of Treg cells
and decrease prevalence of Th1 and Th17 cells. Simulta-
neously, treatment of rhPDCD5 caused the downregulation
of pro-inflammatory cytokine productions and the
upregulation of anti-inflammatory cytokines in the arthritic
rats. These results indicate that the rhPDCD5 may be
beneficial for the treatment of autoimmune arthritis. It
should be noted that this study only partially explored the
regulation of rhPDCD5 on cellular immunity. The influ-
ence of rhPDCD5 on humoral immunity will be further
investigated.
Immunologically, Tregs comprise a subset of CD4+
lymphocytes that suppresses activation, proliferation, and
effector responses of both innate and adaptive immune
cells [23, 24]. Defects in Treg function have been
demonstrated to lead to failed tolerance in human
autoimmune diseases including RA [25]. Tregs can
secrete TGF-β1 and IL-10 which suppress effecter T cell
proliferation and cytokine production. It is thought that
TGF-β1 can contribute to self-reactive T cell apoptosis
and the maintenance of tolerance during lymphocyte mat-
uration, thereby preventing the development of autoimmu-
nity. The results of this study show that the administration
Fig. 3. rhPDCD5 increases the percentages of Tregs and reduces the population of Th1 and Th17. Representative data of CD4+CD25+Foxp3+ cells analyzed
by flow cytometry in draining lymph node (a), spleen (b), and PBMC (c). d Quantification of the proportion of CD4+CD25+Foxp3+ Tregs in lymph node,
spleen, and PBMC. e Quantification of the percentage of CD4+IFN-γ+ and CD4+IL-17A+ cells in lymph node. Results are expressed as means±SD
(*P<0.05, ** P<0.005; #P<0.05, n=6).
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of rhPDCD5 markedly increases the proportions of Tregs
and the levels of TGF-β1 and IL-10 in CIA rats, which
partly explain the immunosuppression effect of PDCD5 on
the occurrence and development of CIA.
The Th17 subset is today recognized as a major player
in synovial inflammation and bone erosion, mainly by the
production of IL-17 [26, 27]. In fact, the pivotal role of
Th17 in the pathogenesis of RA has been increasingly
recognized as taking place via actions ascribed to IL-17.
It is not clear whether Th17 cells consist of a specialized
Th1 subtype or a different phenotype that would act in
concert with Th1 cells. Several in vivo animal models and
in vitro human studies have suggested that Th17 cells can
be considered a decisive mediator of RA. The expression
of IL-17 in the synovium and serum has been associated
with the disease severity of RA [28]. Recently, two IL-17-
Fig. 4. rhPDCD5 reduces the levels of pro-inflammatory cytokines in the serum, synovial, and culture supernatant. Serum (a) and synovia (b) were collected
from the four groups on day 28, and cytokine concentrations were determined by ELISA. Data are means±SD (*P<0.05, ** P<0.005, and ***P<0.0005;
#p<0.05, n=6). Draining LNCs (c) and splenocytes (d) were obtained from four groups and cultured with CII (20 μg/ml) for 48 h, and the cytokine
concentrations in the culture supernatants were determined by ELISA. Data are means±SD (*P<0.05, **P<0.005, and ***P<0.0005, n=6).
Fig. 5. rhPDCD5 suppresses CII-induced cell proliferation and promotes cell apoptosis. a LNCs and splenocytes were obtained from the four groups on day
28 and cultured in the presence of CII (20μg/ml) for 48 h. Cell proliferation was determined by the uptake of [3H] thymidine incorporation. Data are means±
SD (*P<0.05, **P<0.005, and ***P<0.0005, n=6). b LNCs were treated as in a, and cellular apoptosis was analyzed by FITC-Annexin V plus anti-CD4-
PE staining and flow cytometry. Data are means±SD (**P<0.005 and ***P<0.0005; #p<0.05, n=6).
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neutralizing monoclonal antibodies were tested and ap-
peared effective against RA in early stage clinical trials
[29, 30]. Other studies have shown that Tregs can regulate
the Th17 response in the RA patients. In our experiments,
we observed that the increased Tregs stimulated by
rhPDCD5 in CIA rats could downregulate the Th1/Th17
response and suppress the secretion of pro-inflammatory
cytokines (IL-17A, IFN-γ, TNF-α, and IL-6). These re-
sults were similar with EAE model in PDCD5tg mice,
indicating that rhPDCD5 may be an efficient approach to
diminishing exacerbated immune responses in CIA.
Accumulating data proved that rhPDCD5 did not
directly induce apoptosis but rather “primed” cells for
markedly increased sensitivity to tumor cell apoptosis via
different chemotherapeutics [4–7]. Here, we found that
in vitro culture system, the proliferation levels of
splenocytes, and LNCs isolated from rhPDCD5-treated
rats were less potently induced by CII, which were required
for the development of CIA model. Simultaneously,
rhPDCD5-treated CD4+ cells stimulated by CII displayed
the increased apoptosis sensitivity. Therefore, we postulate
that rhPDCD5 treatment may prime self-reactive T cells to
undergo increased activation-induced cell death in re-
sponse to secondary exposure to self antigen and thus
produce its therapeutic benefit by eliminating self-
reactive T cells. In addition, previous report suggested that
the levels of PDCD5 were reduced in RA synovial tissue
(ST) and fibroblast-like synoviocytes (FLS) and the in-
creased PDCD5 expression in RA patient-derived FLS
undergoing apoptosis [16]. In a rat collagen-induced
in vivo model of arthritis, we think that part of rhPDCD5
might enter FLS and increased the sensitivity of apoptosis
which deserves further investigation. This may be one of
the reasons of lower inflammation in rhPDCD5-treated
CIA rats.
As a positive comparison to rhPDCD5 treatment, rats
with CIA were treated with rhTNFR:Fc, an established
therapy for experimental arthritis models and human RA
[31]. In accordance with the results of previous experi-
ments, rhTNFR:Fc has strong ability of suppressing prog-
ress in CIA. It has been shown that the Th1/Th17 cells in
the periphery of RA patients are reduced, and Tregs are
significantly increased after rhTNFR:Fc therapy [32]. In
recent years, there have been many documents reported the
multiple side effects accompanied with anti-TNF-α thera-
pies, such as the increased risk of severe viral and bacteri-
um infection [33, 34], anaphylaxis [35], and tumor [36].
Additionally, their considerable costs still limit their wide-
spread utilization. The scientific community thus begins
making an extraordinary effort to discover novel RA drugs
that target crucial signals of activated cells or others.
This present study together with previous research
[20] implies that the immune-suppressing activity of
rhPDCD5 may have therapeutic benefits for autoim-
munity diseases.
In conclusion, our study provides the comprehensive
assessment of immunosuppressive pathways of rhPDCD5
which induces a potent protective effect against CIA. Fu-
ture studies will be required to determine whether this
novel rhPDCD5-induced pathway can be exploited for
therapeutic benefit.
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